IL27 and type 2 diabetes mellitus: In type 1 and type 2 diabetes, IL-27 exhibits stage-dependent effects; it exacerbates pancreatic β-cell damage in early inflammation but later mitigates disease progression by suppressing Th17 responses and reducing antigen-presenting cell activity.